GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DBV Technologies SA (NAS:DBVT) » Definitions » Retained Earnings

DBVT (DBV Technologies) Retained Earnings : $-263.33 Mil (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is DBV Technologies Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. DBV Technologies's retained earnings for the quarter that ended in Sep. 2024 was $-263.33 Mil.

DBV Technologies's quarterly retained earnings increased from Mar. 2024 ($-266.21 Mil) to Jun. 2024 ($-232.89 Mil) but then declined from Jun. 2024 ($-232.89 Mil) to Sep. 2024 ($-263.33 Mil).

DBV Technologies's annual retained earnings declined from Dec. 2021 ($-258.53 Mil) to Dec. 2022 ($-259.58 Mil) but then increased from Dec. 2022 ($-259.58 Mil) to Dec. 2023 ($-238.86 Mil).


DBV Technologies Retained Earnings Historical Data

The historical data trend for DBV Technologies's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DBV Technologies Retained Earnings Chart

DBV Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -798.99 -958.54 -258.53 -259.58 -238.86

DBV Technologies Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -227.68 -238.86 -266.21 -232.89 -263.33

DBV Technologies Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


DBV Technologies  (NAS:DBVT) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


DBV Technologies Business Description

Traded in Other Exchanges
Address
177-181 avenue Pierre Brossolette, Montrouge, FRA, 92120
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.
Executives
Pharis Mohideen officer: Chief Medical Officer C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451
Daniel Tasse director, officer: Chief Executive Officer C/O IKARIA, INC., 6 STATE ROUTE 173, CLINTON NJ 08809
Adora Ndu director C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Virginie Boucinha officer: Chief Financial Officer C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Timothy E Morris director ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Daniel B Soland director 4560 HORTON STREET,M/S R-422, EMERYVILLE CA 94608
Daniele Guyot-caparros director C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Madduri Ravin Rao director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, #250, AUSTIN TX 78746
Michael Goller director C/O BAKER BROTHERS INVESTMENTS, 667 MADISON AVENUE, 21ST FLOOR, NEW YORK NY 10065
Rosen Michel De director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341